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Background
Vγ9Vδ2 T lymphocytes are regarded as promising mediators of cancer immunotherapy due to
their capacity to eliminate multiple experimental tumors, particularly within those of
hematopoietic origin. However, Vγ9Vδ2 T-cell based lymphoma clinical trials have suffered
from the lack of biomarkers that can be used as prognostic of therapeutic success.
Design and Methods
We have conducted a comprehensive study of gene expression in acute lymphoblastic
leukemias and non-Hodgkin’s lymphomas, aimed at identifying markers of susceptibility ver-
sus resistance to Vγ9Vδ2 T cell-mediated cytotoxicity. We employed cDNA microarrays and
quantitative real-time PCR to screen 20 leukemia and lymphoma cell lines, and 23 primary
hematopoietic tumor samples. These data were analyzed using state-of-the-art bioinformatics,
and gene expression patterns were correlated with susceptibility to Vγ9Vδ2 T cell mediated
cytolysis in vitro. 
Results
We identified a panel of 10 genes encoding cell surface proteins that were statistically differen-
tially expressed between “γδ-susceptible” and “γδ-resistant” hematopoietic tumors. Within this
panel, 3 genes (ULBP1, TFR2 and IFITM1) were associated with increased susceptibility to
Vγ9Vδ2 T-cell cytotoxicity, whereas the other 7 (CLEC2D, NRP2, SELL, PKD2, KCNK12,
ITGA6 and SLAMF1) were enriched in resistant tumors. Furthermore, some of these candidates
displayed a striking variance of expression among primary follicular lymphomas and T-cell
acute lymphoblastic leukemias.
Conclusions
Our results suggest that hematopoietic tumors display a highly variable repertoire of surface
proteins that can impact on Vγ9Vδ2 cell-mediated immunotargeting. The prognostic value of
the proposed markers can now be evaluated in upcoming Vγ9Vδ2 T cell-based
lymphoma/leukemia clinical trials.
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Introduction
γδ T lymphocytes display potent innate anti-tumor
activity in both humans1 and mice.2,3 For example, mice
genetically devoid of γδ T cells displayed increased sus-
ceptibility to skin tumor development induced experi-
mentally by carcinogens,2,3 and to transgenic adenocarci-
noma of the mouse prostate model (TRAMP).4 More
importantly, murine γδ T cells were shown to prevent
(through perforin-mediated cytotoxicity) the develop-
ment of spontaneous B-cell lymphomas.5
The major γδ T-cell subset in human peripheral blood,
Vγ9Vδ2 T lymphocytes, exert potent cytotoxicity
towards tumor cell lines upon activation with small non-
peptidic prenyl pyrophosphate intermediates of iso-
prenoid biosynthesis.6 We and others have shown that,
among such “phosphoantigens”, 4-hydroxy-3-methyl-
but-2-enylpyrophosphate (HMB-PP), a metabolite found
in Eubacteria and Protozoa, is a very potent agonist of the
Vγ9Vδ2 T-cell receptor (TCR) that promotes cytotoxicity
and the secretion of anti-tumor cytokines such as inter-
feron-γ (IFN-γ) and tumor necrosis factor α (TNF-α).6,7
Phosphoantigen-activated Vγ9Vδ2 T cells can kill vari-
ous solid tumor cell lines,1 and a particularly large num-
ber of hematopoietic cell-derived tumors,7-9 as well as
freshly isolated tumor cells from patients with follicular
B-cell lymphoma or chronic lymphocytic leukemia
(CLL).10
The well-established anti-tumor activity of Vγ9Vδ2 T
cells has been recently explored in clinical trials for
solid/epithelial11-13 or liquid/hematopoietic tumors (14-
16), which were collectively promising even though they
showed limited success. The lack of response to therapy
of some patients was attributed to deficient expansion of
effector Vγ9Vδ2 T cells.11,13,14 However, a large proportion
of patients exhibiting significant and sustained in vivo
activation and proliferation of Vγ9Vδ2 T cells also failed
to respond to treatment. Thus, in both prostate carcino-
ma11 and non-Hodgkin’s lymphoma,14 objective respons-
es (partial remissions) were observed in just 33% of the
patients who activated/expanded their Vγ9Vδ2 T cells.
These data emphasize the need for tumor biomarkers
with prognostic value for γδ peripheral blood lympho-
cyte (γδ-PBL)-mediated immunotherapy. 
Here we have conducted a comprehensive genome-
wide expression study aimed at identifying
lymphoma/leukemia markers of susceptibility or resist-
ance to γδ-PBL cytotoxicity. We set up an experimental
system consisting of lymphoma/leukemia cell lines with
various degrees of susceptibility to γδ-PBL-mediated
lysis, and performed comparative cDNA microarray
analyses to characterize their gene expression profiles.
These were validated through bioinformatics and quan-
titative real-time PCR (RT-qPCR), allowing us to define a
panel of 10 candidate biomarkers whose expression dis-
played very marked variability among non-Hodgkin’s
lymphoma and acute lymphoblastic leukemia patients. 
Design and Methods
In vitro cultures of human γδ-PBL and tumor cell lines  
Peripheral blood was collected from healthy volunteers and
peripheral blood mononuclear cells (PBMCs) were isolated as pre-
viously described.7 γδ−PBL were expanded from isolated PBMCs
for 12 days in RPMI 1640 complete media7 supplemented with
100 U/mL of rhIL-2 (Roche Applied Science) and 1 nM HMB-PP
(4-hydroxy-3-methyl-but-2-enylpyrophosphate) (Sup-RPMI). The
percentage of Vγ9+ T cells in peripheral blood increased from 3-
14% at day 0 to 90-98% at day 12 (Online Supplementary Figure S1).
All tumor cell lines were cultured in complete 10% RPMI-1640 as
previously described.7
Leukemia and lymphoma primary samples
Pediatric B- or T-cell acute lymphoblastic leukemia cells contain-
ing high (> 80%) leukemia involvement were obtained from the
peripheral blood and/or the bone marrow of patients at presenta-
tion after informed consent and institutional review board
approval (Instituto Português de Oncologia, Lisbon, Portugal) had
been obtained. Fresh leukemia samples were enriched by density
centrifugation over Ficoll-Paque and then washed twice in 10%
RPMI-1640 medium supplemented with 2 mM L-glutamine (Sup-
RPMI). For lymphoma biopsies, lymph nodes were surgically
removed, immediately frozen in liquid nitrogen and kept at -80ºC
until further use (Department of Pathology, Hospital de Santa
Maria, CHLN, Lisbon, Portugal). Upon diagnosis, we selected
lymph nodes from lymphoma cases and reactive lymph nodes for
our studies.
In vitro killing assays
For cytotoxicity assays, tumor cells (cell lines or primary sam-
ples) were stained with DDAO-SE (Molecular Probes, Invitrogen)
and incubated at a ratio of 1:10 with γδ T cells in Sup-RPMI.
Typically, 3¥105 HMB-PP-activated γδ-PBL (>90% Vγ9+) were co-
incubated with 3¥104 tumor cells (pre-labeled with 1 μM DDAO-
SE) for 3-4h, then stained with Annexin V-FITC (BD Biosciences)
and analyzed by flow cytometry. 
RNA isolation, RT-qPCR and Affymetrix Microarrays
Total RNA from tumor cell lines was extracted using the
RNeasy Mini Kit according to the manufacturer’s instructions
(Qiagen, Hilden, Germany). RNA from leukemia cells and samples
was extracted with TRIzol Reagent (Invitrogen) and purified with
RNeasy Mini Kit according to the manufacturer’s instructions.
Concentration and purity was determined by spectrophotometry
and integrity was confirmed using an Agilent 2100 Bioanalyzer
with an RNA 6000 Nano Assay (Agilent Technologies, Palo Alto,
CA, USA). Total RNA was reverse-transcribed into cDNA as pre-
viously described.7 qPCR was performed on Rotor-Gene 6000
(Corbett) using SYBR Green detection system (PE Applied
Biosystems). Glucoronidase beta (GUSB) and proteasome subunit
beta type 6 (PSMB6) were used as endogenous controls in relative
quantification using the standard curve method. Primers were
designed using the Roche Design Centre (for sequences see Online
Supplementary Table S1). 
For genome-wide analyses, RNA from two independent cul-
tures of each cell line (DAUDI, RAJI, RCH-ACV and 697) was
processed for use on Affymetrix (Santa Clara, CA, USA)
GeneChip HuGene 1.0 ST Arrays, according to the manufacturer’s
Whole Transcript Sense Target Labeling Assay. 
Microarray data analysis
All the microarray data analysis was performed with R and sev-
eral packages available from CRAN17 and Bioconductor.18 The raw
data (CEL files) were normalized and summarized with the
Robust MultiArray Average method from the “affy” package.19
Unsupervised clustering analysis of the gene expression profiles
for entire probe set data was assessed through hierarchical cluster-
ing (Euclidean distance and complete agglomeration method) and
principal component analysis (prcomp function which calls a sin-
A.Q. Gomes et al.
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gular value decomposition method for non-symmetric matrices)
as implemented in the statistical computing package.17
Differentially expressed genes for each comparison were selected
using linear models and empirical Bayes methods20 as implement-
ed in the Limma package,21 verifying the P values corresponding to
moderated F-statistics, and selecting as differentially expressed
genes those that had adjusted P values adjusted using the
Benjamini and Hochberg method22 lower than 0.05.
The enrichment of biological functions and pathways was ana-
lyzed using Ingenuity Pathway Analysis software (Ingenuity
Systems, Mountain View, CA, USA) and all genes present in the
Affymetrix Human Gene 1.0 ST as control.
Results
Highly variable susceptibility of acute leukemias and
non-Hodgkin’s lymphomas to γδ-PBL cytotoxicity 
In our laboratory we have studied a collection of 23
samples of acute lymphoblastic leukemias and non-
Hodgkin’s lymphomas, and a panel of 20 tumor cell lines
of hematopoietic origin. The latter included acute lym-
phoblastic leukemia (ALL) (JURKAT, MOLT4, RCH-
ACV, 697, CEM, TOM-1, RS4-11, B15, REH, Bv173) and
acute myelogenous leukemia (AML) (HL-60, HEL, THP-
1) cell lines; and non-Hodgkin Burkitt’s (DAUDI, RAJI,
RAMOS), follicular (DOHH2) and lymphoblastic (Oz)
lymphoma cell lines (for detailed description of these cell
lines see Online Supplementary Table S2). Although the
capacity of peripheral blood γδ T cells to target multiple
tumor cell lines of hematopoietic origin is well docu-
mented,7-9 we observed that a substantial fraction of cell
lines (Figure 1A and B) and patient samples (Figure 1A
and data not shown) were strikingly resistant to γδ-PBL
(obtained from healthy donors) pre-activated (as illus-
trated by high CD69 levels) with HMB-PP, the most
potent natural Vγ9Vδ2 T-cell activator known to date (6,
7) (Online Supplementary Figure S1). For example, the B-
ALL cell lines Bv173, REH and 697 (Figure 1 A and B), and
six primary samples obtained from B-ALL patients
(Figure 1A and data not shown) remained mostly alive
(Annexin V-) in co-cultures with fully-activated (100%
CD69+; data not shown) γδ-PBL. Similar data were
obtained with primary T-ALL samples and the cell line
CEM (Figure 1A). This resistance to γδ-PBL cytotoxicity
contrasted sharply with the extensive killing observed
for the B-ALL line RCH-ACV and the T-ALL line MOLT-
4 (Figure 1A), among various other hematopoietic
tumors (Figure 1B). 
For systematic analysis of our killing assay data, we
considered tumor samples with over 70% lysis as sus-
ceptible to γδ-PBL-mediated lysis (“γδ-susceptible”), and
those under 30% lysed as “γδ-resistant”. Importantly,
susceptibility was independent of the γδ-PBL donor, as
the pattern of susceptible/resistant lines was equivalent
for 3 independent healthy donors (Online Supplementary
Figure S2A). Moreover, the differences in susceptibility to
γδ T cells were maintained when tumor cell lines were
incubated with γδ T cells activated for a shorter time
(12h) (Online Supplementary Figure S2B), further support-
ing the segregation between susceptible and resistant cell
Vγ9Vδ2 cell-mediated immunotargeting
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Figure 1. Differential susceptibility of
leukemia and lymphoma cells to γδ-PBL
cytotoxicity. (A) Annexin V staining for apop-
totic tumor cells after 4 h of co-incubation
with HMB-PP-activated γδ-PBL. Tumors were
B-ALL (left panels) or T-ALL (right panels)
cells, either primary samples or the indicat-
ed cell lines. (B) Summary of killing assays
(as in A) with 20 leukemia or lymphoma cell
lines (described in Online Supplementary
Table S2). Error bars correspond to triplicate
assays. (C) Effect of increasing concentra-
tions of H2O2 on leukemia/lymphoma cell































































































lines. As primary samples to reproduce and expand
experiments aimed at dissecting the molecular mecha-
nisms of tumor susceptibility to γδ-PBL cytotoxicity are
difficult to obtain, we focused on our well-established
panel of cell lines for the initial candidate searches and
later extended our findings to patient samples.
We first considered that tumor resistance to γδ-PBL
cytotoxicity could stem from intrinsic anti-apoptotic
mechanisms developed by some leukemia/lymphoma
cell lines. However, when we tested the effect of a pro-
apoptotic stimulus (H2O2) we observed no association
between resistance to apoptosis and to γδ-PBL cytotoxi-
city. Namely, the cell lines Jurkat (γδ-susceptible) and
REH (γδ-resistant) were more sensitive to non-saturating
concentrations of H2O2 than the cell lines MOLT-4 (γδ-
susceptible) and RAJI (γδ-resistant) (Figure 1C). This sug-
gests that susceptibility to γδ-PBL cytotoxicity is not
related to the response to other death stimuli and proba-
bly involves a specific protein expression program
(involved in tumor/γδ-PBL interactions) that we set out
to characterize. 
Genome-wide comparisons between γδ-susceptible and
γδ-resistant hematopoietic tumors
The observed differences in susceptibility γδ-PBL cyto-
toxicity among hematopoietic tumors emphasize the
importance of defining gene signatures that may predict
the effectiveness of γδ T-cell based immunotherapies in
the clinic. We performed a genome-wide analysis aimed
at comparing the mRNA expression profiles of γδ-sus-
ceptible and γδ-resistant tumors. We employed cDNA
microarrays to examine two pairs of hematopoietic
tumor cell lines sharing the same cytogenetic alterations
and cellular phenotypes (Online Supplementary Table S2):
the Burkitt’s lymphomas DAUDI (susceptible) and RAJI
(resistant), and the B-ALL lines RCH-ACV (susceptible)
and 697 (resistant). 
First, samples were grouped according to the similarity
of gene expression patterns using unsupervised cluster-
ing analysis (no group specification a priori). Based on the
entire probe set data, two main groups could be defined
which corresponded to the original cell type (Figure 2A):
pre-B (697 and RCH-ACV) and mature B cells (DAUDI
and RAJI). We next applied principal component analysis
(PCA), which identifies new variables, to the principal
components, which are linear combinations of the origi-
nal variables (gene expression levels) and represent the
largest variation found between samples.23 Although the
original cell type was the major source of variation
between all samples (53.3% of total variation), PCA
showed that component 3 was responsible for the segre-
gation (16.4% of total variation) according to the suscep-
tibility to γδ-PBL cytotoxicity (Figure 2B): susceptible
(DAUDI and RCH-ACV) versus resistant (RAJI and 697). 
To identify gene expression variations associated with
susceptibility to γδ-PBL cytotoxicity, and to suppress the
variations due to the transformed cell type (pre-B or
mature B cells), we first compared tumors with identical
origin, i.e. DAUDI versus RAJI, and RCH-ACV versus 697
(Online Supplementary Tables S3 and S4). We then used
Bayesian linear models20 and selected the common genes
between both analyses: 340 genes (155 up- and 185
down-regulated in γδ-susceptible tumors) presented sim-
ilar gene expression variations and were considered for
further analysis (Online Supplementary Table S5).
Bioinformatics analysis revealed an enrichment for func-
tions related to cell-to-cell signaling and interaction,
hematologic system development and function, immune
A.Q. Gomes et al.
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Figure 2. Comparison of gene expression in tumor cell lines suscep-
tible or resistant to γδ-PBL cytotoxicity. Bioinformatics analyses of
cDNA microarray comparisons between the Burkitt’s lymphomas
DAUDI and RAJI; and the B-ALL lines RCH-ACV and 697. (A)
Unsupervised hierarchical clustering analysis. Samples with similar
gene expression patterns are grouped together and connected with
branches, producing a clustering tree (or dendrogram) on which the
branch length inversely reflects the degree of similarity between
samples. (B) Principal Component Analysis. The samples are plot-
ted according to the first and third principal components (corre-
sponding to the largest variation found between samples). (C)
Variations in expression levels of anti- or pro-apoptotic genes in sus-
ceptible versus resistant tumor cell lines. Dashed lines indicate 2
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cell trafficking (P value < 0.05; Online Supplementary Table
S6). Some of the top pathways affected were interferon
signaling, crosstalk between dendritic cells and natural
killer cells, and molecular mechanisms of cancer (P value
< 0.05; Online Supplementary Table S7). 
The gene expression variations observed also suggest-
ed that, consistent with our previous experimental data
(Figure 1C), the segregation between susceptible and
resistant tumors is not associated with expression of
anti- or pro-apoptotic genes (Figure 2C and Online
Supplementary Table S8). Thus, up-/down-regulation of
pro-/anti-apoptotic genes did not correlate with suscep-
tibility to γδ-PBL cytotoxicity. Moreover, apoptotic relat-
ed functions and pathways were not enriched in the
panel of 340 genes (Online Supplementary Table S7). Based
on these results, we favored the hypothesis that suscep-
tibility or resistance to γδ-PBL cytotoxicity is conferred
by signals presented at the tumor/γδ-PBL interface, i.e.
on the surface of leukemia/lymphoma cells.
A set of cell surface proteins segregates between 
γδ-susceptible and γδ-resistant leukemia/lymphoma
cell lines 
T cells recognize their targets through cell surface anti-
gens. We, therefore, focused our analysis of the panel of
340 genes on those encoding plasma membrane proteins
(with extracellular domains), using a fold change thresh-
old of 2 (log FC >1). These consisted of 8 genes up-regu-
lated and 19 genes down-regulated in γδ-susceptible
tumors when compared to resistant tumors (Online
Supplementary Table S9). The mRNA expression levels of
the 27 candidates were assessed by RT-qPCR (in inde-
pendent samples) to validate the microarray results.
Upon statistical analysis of the data, 22 out of the 27
genes were confirmed as differentially expressed in the
two pairs of cell lines used for microarray comparisons:
of these, 6 genes were up-regulated and 16 genes were
down-regulated in γδ-susceptible tumors (Figure 3A). In
order to have more stringent selection criteria, we
extended our expression studies to a broader panel of cell
lines, including 6 susceptible and 4 resistant cell lines
(Online Supplementary Figure S3). This showed 10 genes
with significant expression variation between suscepti-
ble and resistant tumors (P value < 0.05, Mann-Whitney
test) (Figure 3B). Thus, our final panel of candidate mark-
ers of susceptibility to γδ-PBL cytotoxicity consisted of 3
genes enriched in γδ-suceptible tumors (ULBP1, TFR2
and IFITM1), and 7 genes enriched in γδ-resistant
leukemias/lymphomas (CLEC2D, NRP2, SELL, PKD2,
KCNK12, ITGA6 and SLAMF1) (Table 1).
Heterogeneity of expression of candidate markers in
primary leukemia and lymphoma samples 
We next determined the expression levels of each candi-
date marker in primary samples obtained from T-cell acute
lymphoblastic leukemia (T-ALL) and non-Hodgkin’s lym-
phoma (NHL) patients. Within the latter group, we sam-
pled patients with common indolent (follicular) or aggres-
sive (diffuse large B-cell - DLBCL) lymphomas. Gene
expression levels in samples were compared with healthy
PBMCs (for ALL) and reactive follicles (for NHL), taken as
references (0 on log scale) in Figure 4A and B. Hence, a
positive or negative (log scale) variation indicates higher or
lower expression in tumors than in the control samples,
respectively. Overall, the tumors exhibited very variable
gene expression profiles. For example, among susceptibil-
ity-associated genes, ULBP1 was over-expressed in a large
number of primary samples, while TFR2 was only
enriched in three FL samples (FL 1, FL 2 and FL 8), and
IFITM1 was strongly depleted in various tumors (Figure
4A and B). On the other hand, all resistance-associated
genes were over-expressed in FL sample 3, in contrast to
the majority of primary samples analyzed. Moreover,
there was no essential difference in some markers, such as
ITGA6 or SELL, between the various patients (Figure 4A
and B). Collectively, these data revealed a striking hetero-
geneity in the expression of particular candidate genes in
primary tumors. When compared to our results with
tumor cell lines (Online Supplementary Figure S3), these clin-
ical data possibly reflect distinct selective pressures on the
Vγ9Vδ2 cell-mediated immunotargeting
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Figure 3. Variations in expression of genes encoding cell surface
proteins that segregate between γδ-susceptible and γδ-resistant
leukemia/lymphoma cell lines. (A) RT-qPCR validation of microarray
results for the comparisons of Figure 2. The mRNA expression lev-
els were normalized to GUSB and PSMB6 for each cell line. Plotted
are the averages of relative expression levels in DAUDI versus RAJI
(DAUDI/ RAJI) and RCH-ACV versus 697 (RCH-ACV/ 697). Dashed
lines indicate 2 fold-change values (in logarithmic scale). (B)
Statistical analysis of RT-qPCR results (detailed in Figure 4) in 6 sus-
ceptible and 4 resistant cell lines. Statistical significance was
assessed by Mann-Whitney test (-log P value). Dashed line repre-
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expression of the genes that compose the candidate panel,
the consequence of which should now be evaluated in
clinical trials.
Discussion
The success of immunotherapy to tackle tumors, in
particular those that prevail after chemo- or radiothera-
py, critically depends on two factors: the specific activa-
tion of effector anti-tumor lymphocytes and the molecu-
lar recognition of tumor cells by activated lymphocytes.
Concerning γδ T cells, research over the last 15 years has
identified very potent and specific phosphoantigens,
most notably HMB-PP,6,7 that seem to fulfill the first
requirement. There have been suggestions that phospho-
antigens themselves,6,24,25 or an F1-ATPase-related struc-
ture complexed with delipidated apolipoprotein A-I,26 or
the non-classical MHC protein ULBP427 could be respon-
sible for tumor cell recognition by Vγ9Vδ2 PBL.
However, despite this, the issue is still highly controver-
sial. This naturally impacts on our ability to design effec-
tive therapeutic protocols based on γδ-PBL immunotar-
geting of tumors. Thus, only 33% of patients with
prostate carcinoma11 or non-Hodgkin’s lymphoma14
showed objective responses despite large activation and
expansion of their Vγ9Vδ2 T cells in vivo. These consider-
ations stress the importance of identifying tumor molec-
ular signatures that may predict the response to activat-
ed γδ-PBL.
In this study, we set out to identify cell surface proteins
involved in interactions between leukemia/lymphoma
cells and γδ-PBL. Taking in vitro tumor cytolysis as func-
tional readout, we screened a panel of 20 leukemia and
lymphoma cell lines that faithfully reproduced the sus-
ceptibility/resistance of primary tumors (Figure 1A). The
use of cell lines permitted experimental reproducibility
and hence statistical robustness for the gene expression
undertaken. Upon the identification of candidate mark-
ers, we analyzed their expression in 23 samples derived
from T-ALL and NHL (FL and DLBCL) patients.
The choice of cDNA microarrays as screening tools
was based on a multiplicity of previous studies that
demonstrated how powerful and reliable they are in
defining cancer molecular signatures.28 Our analyses led
to the identification of a large panel of genes differential-
ly expressed between “γδ-susceptible” and “γδ-resistant”
tumors. Importantly, we verified that there was no cor-
relation between intrinsic anti-apoptotic properties and
resistance to γδ-PBL cytotoxicity, both in terms of gene
expression and response to a death stimulus. Thus, sus-
ceptibility or resistance to γδ-mediated lysis is more like-
ly to be related to tumor recognition and immune eva-
sion strategies, the molecular basis of which remains to
be clarified. Of note, MHC class Ia expression did not
consistently segregate between γδ-susceptible and γδ-
resistant tumor cell lines (Online Supplementary Figure S4).
For example, among susceptible lines, DAUDI and
MOLT-4 expressed very low or undetectable levels,
whereas JURKAT and RCH-ACV displayed high levels of
surface MHC class I (Online Supplementary Figure S4).
These data exclude a mechanism of “missing self” as the
basis for γδ T-cell recognition of hematopoietic tumors.
Building upon stringent biological and statistical selec-
tion criteria, we narrowed our microarray data down to
10 genes encoding cell surface proteins (with extracellu-
lar domains), whose expression segregated with suscep-
tibility versus resistance to γδ-PBL cytotoxicity. We
believe it is important to make this gene profile available
to the biomedical community. Thus, we propose the
expression of each candidate gene to be evaluated during
upcoming γδ T-cell based clinical trials. The genes with
highest predictive value will constitute novel
leukemia/lymphoma biomarkers, for which standard-
ized quantification essays should be developed. This will
provide clinicians with a key tool for the indication and
monitoring of γδ T-cell based immunotherapies.
Furthermore, within the panel of 10 candidate mark-
ers, some are likely to play non-redundant roles in
leukemia/lymphoma cell recognition by γδ-PBL. Thus,
proteins that are enriched in γδ-susceptible tumors may
provide activation signals, whereas markers of resistance
may convey inhibitory signals to γδ-PBL. Provocatively, 7
A.Q. Gomes et al.
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Table 1. Panel of cell surface proteins associated with the susceptibility or resistance of lymphomas/leukemias to γδ T-cell cytotoxicity. The sta-
tistical difference between the average gene expression in the 6 susceptible versus the 4 resistant tumors of Figure 4 was assessed by Mann-
Whitney test (P<0.05).
Symbol Description Biological function P value
Enriched in γδ-susceptible tumors
ULBP1 UL16 binding protein Ligand for NKG2D on NK and T cells; 0
induces cytotoxicity, cytokine secretion
IFITM1 Interferon-induced transmembrane protein 1 Involved in cell proliferation and malignancy 0
(CD225)
TFR2 Transferrin receptor 2 Cellular uptake of transferrin-bound iron 0.004
Enriched in γδ-resistant tumors
CLEC2D C-type lectin 2, D Ligand for the NK inhibitory receptor CD161 0.002
SELL Selectin L Adhesion of T cells to endothelial cells 0.001
SLAMF1 Signaling lymphocytic activation molecule 1 Bidirectional T cell to B cell stimulation 0
KCNK12 Potassium channel K, 12 Potassium channel 0
ITGA6 Integrin alpha 6 Integrin; receptor for laminin  0.014
PKD2 Polycystic kidney disease 2 Calcium channel 0.017
NRP2 Neuropilin 2 Co-receptor for VEGF; implicated in tumor 0.018
growth and vascularization
of the candidates are known to intervene in immune
responses: 4 of them (ULBP1, IFITM1, CLEC2D and
SLAMF1) provide stimulatory (or inhibitory) signals
through receptors expressed on lymphocytes, while 3
(NRP2, SELL and ITGA6) control lymphocyte adhesion.
ULBP1 is a ligand for the NKG2D receptor expressed on
all cytotoxic lymphocyte lineages, including 100% of
Vγ9Vδ2 T cells, which has been clearly implicated in
anti-tumor responses.29-32 IFITM1 was shown to modu-
late NK cell responses and its expression correlated with
improved survival of gastric cancer patients.33 By con-
trast, the expression of CLEC2D, a ligand for the
inhibitory receptor CD161, inhibits NK cell responses
and was associated with increased malignancy grade of
glioblastoma.34 NRP2 is another protein that can favor
cancer progression by acting as a coreceptor for vascular
endothelial growth factor (VEGF) and stimulating tumor
growth (35). We will now proceed with individual
knock-down (RNA interference) experiments in a func-
tional (tumor killing) bioassay to dissect the role of each
of the candidates in γδ-PBL targeting of leukemias and
lymphomas. Given that some of these molecules can also
provide costimulatory or inhibitory signals to NK cells,
we also plan to address their role in NK cell targeting of
hematopoietic malignancies.
In summary, this report establishes a panel of 10 puta-
tive markers of leukemia/lymphoma susceptibility to γδ-
PBL cytotoxicity. The expression data collected from pri-
mary samples showed a striking heterogeneity for partic-
ular candidate genes, most notably ULBP1, whereas
other genes, such as IFITM1, ITGA6 or SELL, essentially
did not vary among patients. It is, therefore, predictable
that different components of the proposed panel will
behave in very distinct ways when associated to thera-
peutic outcome in clinical trials. It will also be interesting
to evaluate to what extent immunoselection may have
conditioned the expression of these markers in tumors
evolving in a dynamic interaction with γδ T lympho-
cytes. This will significantly add to our understanding of
anti-tumor immunity and to our capacity to modulate it
for cancer immunotherapy.
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Figure 4. Quantification of mRNA
expression levels of γδ-susceptibil-
ity markers in acute lymphoblas-
tic leukemia and non-Hodgkin’s
lymphoma patients. (A) RT-qPCR
analysis of mRNA expression in
11 T-cell acute lymphoblastic
leukemia (T-ALL) samples, nor-
malized to housekeeping genes
(GUSB and PSMB6) and to refer-
ence PBMCs from healthy individ-
uals. Values were converted to
logarithmic scale. (B) RT-qPCR
analysis of mRNA expression in 8
follicular lymphoma (FL) and 4 dif-
fuse large B cell lymphoma
(DLBCL) samples, normalized to
housekeeping genes (GUSB and
PSMB6) and to a reference sam-
ple - reactive follicles – obtained
through the same procedure.
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